MedTrace Logo

GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA)

NCT00681655 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2022-04-07

No results posted yet for this study

Summary

This study will assess whether the presence of a particular form of a gene, GABRA2, affects the functional responses of the human brain to alcohol administration and will evaluate that relationship in the context of factors known to increase the risk for future alcoholism.

Conditions

  • Alcoholism

Interventions

OTHER

Alcohol

Alcohol (6% in saline vehicle) infused for 2.8 hour long clamping session (Breath alcohol level maintained at 60 mg/dL throughout).

OTHER

Placebo

Placebo (saline vehicle) infused for 2.8 hour long session.

Sponsors & Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    collaborator NIH

  • Indiana University

    lead OTHER

Principal Investigators

  • Martin H Plawecki, M.D. · Indiana University School of Medicine

  • Sean J. O'Connor, M.D. · Indiana University School of Medicine

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
27 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2012-04-14
Completion
2012-04-14

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00681655 on ClinicalTrials.gov